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Cardiovascular factors are one of the main causes of morbidity and mortality in patients with
chronic kidney disease. Bone mineral metabolism disorders and inﬂammation are patho-
logical conditions that involve increased cardiovascular risk in chronic kidney disease. The
cardiovascular risk involvement of bone mineral metabolism classical biochemical param-
eters such as phosphorus, calcium, vitamin D and PTH is well known. The newest markers,
FGF23 and klotho, could also be implicated in cardiovascular disease.
©  2016 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Una de las principales causas de morbimortalidad en el paciente con enfermedad renal
crónica es la cardiovascular. La inﬂamación y las alteraciones en el metabolismo óseo min-
eral  son una condición patológica que conlleva aumento del riesgo cardiovascular en la
enfermedad renal crónica. Los parámetros bioquímicos clásicos del metabolismo óseo min-
eral como fósforo, calcio, vitamina D y PTH tienen una implicación muy conocida en el riesgouevocardiovascular. Los nen  la enfermedad cardiov
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ntroduction
hronic kidney disease (CKD) is a public health problem that is
n the rise, with an ever-increasing incidence and prevalence
10% of the general population).1,2 The main cause of mortality
n the CKD patient is cardiovascular (CV),3 with an increase in
isk of up to 20 times that of the general population, even in ini-
ial stages.4–6 Up to 80% of patients with CKD have associated
V disease: hypertension (36%), ischaemic cardiomyopathy
22–39%), atrial ﬁbrillation (30%), valvular heart disease (24%)
nd left ventricular hypertrophy (LVH) (50–75% in stage 3–4
KD).7,8
ardiovascular  risk  factors  in  the  chronic
idney  disease  patient
he greater cardiovascular risk (CVR) of patients with CKD is
xplained by the high presence of classic risk factors and the
verlapping of speciﬁc factors of a uraemic state as well as
y the inﬂammatory state of CKD; stage 5 adds other fac-
ors related to dialysis or transplant that causes an excess
f vascular calciﬁcation9,10 (Fig. 1). Bone mineral disorder
elated to CKD (BMD-CKD) plays a crucial role in CKD mor-
idity and mortality. BMD-CKD includes clinical-chemistry
nd skeletal abnormalities and extraskeletal calciﬁcations
aused by abnormalities in mineral metabolism in CKD. CKD-
BD  I presents as one or a combination of the following
anifestations11:
 Abnormalities in calcium (Ca), phosphate (P), parathyroid
hormone (PTH) and vitamin D, klotho, or ﬁbroblast growth
factor 23 (FGF23).
 Abnormalities in skeletal remodelling, mineralisation, vol-
ume,  growth or fragility.
 Calciﬁcations of cardiovascular or other soft tissues.
Studying markers of BMD-CKD sometimes allows CVR to be
redicted. Table 1 summarises the role of the factors involved
n BMD-CKD. The role of klotho and FGF23 in CVD is reviewed
elow.GF23
his is a 32-kDa, 251-amino acid protein synthesised and
ecreted by bone cells, mainly osteocytes. It belongs to the
Classic CV risk fac
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Fig. 1 – CVR factors involved in re(4):368–375 369
“phosphatonin” hormone group12 owing to its involvement
in renal phosphorus elimination. It has been pathophysi-
ologically linked to the so-called “rare hypophosphataemic
syndromes”,13 characterised by mineralisation defects and
bone deformities, hypophosphataemia, renal P loss and inap-
propriately low calcitriol levels. It is considered to be one of
the main factors in P metabolism regulation.14–16 The biolog-
ical action of FGF23 depends on the klotho gene14,17–19 which
acts as its co-receptor. FGF23 is also expressed in the heart,
liver, thyroid gland, parathyroid glands, intestine and skeletal
muscle.19
FGF23  regulation
FGF23 regulation is determined by:
1. Active vitamin D: calcitriol directly and indirectly increases
FGF23 transcription through extracellular signalling path-
ways mediated by leptin and interleukin 6.20 Calcitriol also
increases expression of the nuclear receptor associated
with protein 1 (Nurr1) in bone cells and of PTH, which leads
to an increase in FGF23.21
2. Ca levels: high calcium stimulate FGF23 secretion.22,23
3. Hyperparathyroidism: the increase in PTH linked to CKD
may stimulate FGF23 secretion through Nurr1.19,21 In
primary hyperparathyroidism (PHPTH), FGF23 would hypo-
thetically be suppressed since PTH hypersecretion would
cause hypophosphataemia so one important stimuli of
FGF23 secretion would be reduced.24 However, experi-
mental studies have demonstrated that mice with PHPTH
have higher FGF23 levels than controls and that PTH
directly stimulate FGF23,25 since FGF23 decreases following
parathyroidectomy.25 Yamashita et al.24 demonstrated in
patients with PHPTH that FGF23 levels were high compared
to healthy controls. However, in this same study, patients
without CKD or PHPTH had no differences in FGF23 lev-
els compared to controls,24 and the authors concluded that
in PHPTH renal function is a determining factor in FGF23
levels.24
4. P levels: serum P levels have been positively correlated
with FGF23 concentration in patients with CKD.26 How-
ever, restricting dietary P in patients with CKD has shown
contradictory results in FGF23 levels. Some studies have
demonstrated that restricting dietary P fails to cause a drop
in FGF23 levels in patients with stage 3–4 CKD27 and does
tors
tion
tic
ivation
s
ction
nal and cardiac impairment.
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Table 1 – Regulation of bone mineral disorder related to chronic kidney disease.
PTH Active vit. D FGF23 Klotho
Synthesis Parathyroid glands 25OHD3: hepatic
1,25(OH)2D3: kidneys,
monocytes
Bone (osteoblasts) Kidneys
Choroid plexus, parathyroid
glands
Regulation Stimulants: Ca, P
Inhibitors:Vitamin D,
FGF23
Stimulation of 1-hydroxylase:
PTH, growth hormone,
prolactin
Inhibition of 1-hydroxylase:
FGF23, klotho
Stimulation of 24-hydroxylase:
vitamin D analogues,
FGF23
Stimulation:FGF23,
PTH, Nurr1, P
overload, Ca
Stimulation: PPAR ,
vitamin D
Inhibits: angiotensin II,
FGF23, inﬂammation
Bone actions Increase in bone
reabsorption: release
of Ca and P into
blood
Stimulation of FGF23
secretion
Increase in bone
resorption
Stimulates FGF23
synthesis
Renal action Increases Ca
reabsorption and
inhibits P
reabsorption
Stimulates
1-hydroxylase
Phosphaturic  action
Inhibits
1-hydroxylase and
activates
24-hydroxylase
Increases phosphaturia
(FGF23)
Inhibits 1-hydroxylase
Ca reabsorption
Intestinal action Indirectly by
stimulating calcitriol
Ca and P absorption
Other actions Uraemic toxin PTH inhibition
Pleiotropism
RAAS inhibition
Inhibits  PTH, LVH? Antioxidant
Antiapoptotic
Endothelial protection
Protection from renalnot change them in healthy volunteers.28 Despite this, a
drop in P absorption with phosphate binders such as seve-
lamer causes a drop in FGF23 levels.29,30
5. Reduced renal synthesis of klotho: FGF23’s afﬁnity for its
receptor (especially FGFR1 in the kidneys) is very low.31
Under physiological conditions, when bound to FGFR1,
FGF23 would be unable to generate signal transduction.31 In
the presence of klotho, FGF23 afﬁnity for its receptor FGFR1
increases signiﬁcantly and allows its activation with phys-
iological concentration of FGF23.31 A reduction of klotho
expression could cause resistance to the action of FGF23;
in CKD this resistance would lead to a reduction in the
fractional excretion of P and an increase in serum P con-
centration which in turn stimulate FGF23 secretion.32
Interestingly, iron infusion and low iron levels may induce
synthesis of FGF23, although not in its active form.22 Metabolic
acidosis, oestrogens and leptin also cause increases in
FGF23.33,34
Biological  actions  of  FGF23FGF23 has target receptors called FGFR1, FGFR3 and FGFR4
and the transmembrane receptor -glucuronidase. To exert
its action on FGFR1 in the kidneys it requires its co-receptor
klotho.31,35failure
Protection against LVH
• Bone: in those processes characterised by a mineralisation
defect (rickets and osteomalacia) there is excessive pro-
duction and high activity of FGF23.36 Various groups are
researching the direct effect of FGF23 on bone; however,
evidence of a direct effect of FGF23 on bone has not yet
been demonstrated.37 Various proteins, predominantly in
bone, have been found to be involved in regulation of FGF23
synthesis and secretion. These proteins include Phex (P-
regulating endopeptidase linked to the X chromosome) and
glycoproteins such as that derived from the dentine pro-
tein matrix (DMP1) and from the extracellular matrix.36,37
Abnormalities of these proteins cause an increase in FGF23
expression, thereby enhancing phosphaturia resulting in
hypophosphataemia and inhibition of bone formation.36,37
Abnormal GLANT expression produces the opposite effect:
a decrease in FGF23 activity with an increase in serum P
levels and soft tissue calciﬁcation (tumoral calcinosis).38
• Kidneys: inhibit the expression of type II sodium-phosphate
co-transporters (IIa Na/P and IIc Na/P), which causes a
decrease tubular reabsorption of P in the proximal tubules
thus increasing renal P excretion.17,19,39 It also decreases
calcitriol levels by suppressing the activity of the enzyme
1-hydroxylase (CYP27B1) and stimulating the enzyme 24-
hydroxylase (CYP24A1).19,39,40 Finally, in the kidneys, it
41inhibits transcription of the klotho gene.
• Parathyroid glands: FGF23 decreases PTH production and
secretion; this has been demonstrated by several research
groups: works such as those by Ben-Dov et al.42 and
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Krajisnik et al.43 have indicated that FGF23 causes PTH sup-
pression in vivo and in vitro and decreases mRNA  expression
and transcription and PTH protein secretion.43 However,
in hyperplastic uraemic parathyroid glands in rats, FGF23
fails in PTH inhibition compared to healthy parathyroid
glands, perhaps owing to a drop in FGFR1 and klotho
expression in uraemic hyperplastic glands.44 The impact
of parathyroidectomy on FGF23 levels in patients with CKD
was studied by Takahashi et al.,45 who designed a study in
30 patients in haemodialysis treated by means of parathy-
roidectomy with forearm implant and determined FGF23
and klotho levels. They concluded that FGF23 dropped and
that klotho had an initial drop and a subsequent increase
compared to post-parathyroidectomy values.
 Heart: in cardiac muscle cells in mice it has been demon-
strated that, through its receptor (FGFR4), FGF23 activates
the nuclear factor of activated T cells (NFAT)/calcineurin
pathway and causes LVH independently of klotho.46
nvolvement  of  FGF23  in  CKD  and  CVR
he patient with end-stage CKD may have FGF23 values of up
o 100 times their normal value28; in addition, high FGF23 lev-
ls predict CKD progression, as conﬁrmed by several studies
47–49 High FGF23 levels are associated with an increase in mor-
ality adjusted for classic cardiovascular risk factors and other
raditional CKD markers.47,50
An association between FGF23 and vascular calciﬁcation
as been demonstrated, although FGF23 does not seem to
nduce calciﬁcation directly.51 Scialla et al.51 studied the
ssociation between FGF23, P, coronary calciﬁcation and cal-
iﬁcation of the thoracic aorta measured by a CT scan in
501 participants with CKD (mean glomerular ﬁltration rate
GFR] of 47 ± 17 ml/min/1.73 m2; stages 2–4). These authors
emonstrated that FGF23 was not associated with vascular
alciﬁcation measured by a CT scan and, in in vitro studies,
GF23 did not cause calciﬁcation or induce calciﬁcation in of
ultured vascular smooth muscle cells (VSMCs), and it is not
ound in the aorta of mice or humans.51 The role of FGF23
n vascular calciﬁcation would be marked by hyperphos-
hataemia which does induce vascular calciﬁcation; VSMCs
how osteoblast differentiation in a P-rich media.52,53 It seems
o be an association between severity of calciﬁcation and
GF23 in CKD, and so FGF23 could be a marker for follow-up
nd not a factor in the generation of vascular calciﬁcation.51
Excess FGF23 leads to an increase in CV morbidity and mor-
ality in CKD54,55 independently of the GFR.56 This could be
ue:
. To the fact that FGF23 reduces active vitamin D (calcitriol)
levels as it inhibits 1-hydroxylase and stimulates 24-
hydroxylase.19,39
. To the fact that FGF23 is linked to the presence of markers
of inﬂammation57,58 and oxidative stress such as advanced
glycation end products which are associated with vascular
calciﬁcation.57
. To the fact that, in some studies, FGF23 has been associated
with proteinuria.59(4):368–375 371
4. To the role of FGF23 in genesis of LVH (a signiﬁcant source
of arrhythmias and heart failure): an elegant study by Faul
et al.46 showed, in a cohort of more  than 3,000 patients
with CKD with a GFR of 20–70 ml/min, that there was a cor-
relation between FGF23 levels and LVH. This same study
described that FGF23 caused an increase in -actin in car-
diac muscle cells in rats with an increase in expression of
LVH markers, such as foetal heavy chain -myosin, and a
drop in adult heavy chain -myosin. This mechanism is
independent of klotho and is mediated by activation of the
NFAT/calcineurin pathway.
Klotho
This is a 130-kDa transmembrane protein that is expressed
predominantly in the kidneys (distal, proximal and col-
lecting tubule), parathyroid glands, choroid plexus and
endothelium.60,61 It has 3 different forms62,63: klotho-cut, with
little biological effect; the complete form, bound to the mem-
brane (which acts as an FGF23 co-receptor); and the secreted
form.
Klotho  regulation
1. In experimental models in vitro it has been demon-
strated that the peroxisome proliferator activated receptor
 (PPAR ) signal64 increases klotho synthesis. Calcitriol also
increases expression of klotho in animal models with CKD
and high P intake.65
2. Factors that decrease klotho synthesis are: FGF23,66–68
oxidative stress69 and angiotensin II (through its type I
receptors and through an increase in tumour necrosis
factor- converting enzyme [TACE]).17,70,71 The klotho gene,
which is predominantly synthesised in the kidneys, is
decreased in patients with CKD.62,72
Biological  actions  of  klotho
• Kidneys: klotho directly induces phosphaturia, acting in the
proximal tubules by inhibiting type IIa and type IIc Na/P
co-transporters.72–74 In addition, klotho is an FGFR-1 co-
receptor and, therefore, facilitates the phosphaturic action
of FGF23.62,63 At the same time, it also regulates Ca homeo-
stasis by modulating the transient receptor potential ion
channel (TRPV5)75 and potassium (K) renal channels by reg-
ulating the renal outer medullary K (ROMK1) channel.76
• Endothelium: klotho may inhibit vascular calciﬁcation; a
decrease in klotho is associated with an increase in expres-
sion of P transporters PiT1/2 and of the Runx2 osteogenic
factor, which would lead to an increase in P transport in
VSMCs and their osteogenic transformation.77,78 However,
the studies on klotho expression in the vasculature have
been contradictory. Lim et al.79 showed its expression in
the arteries of healthy individuals; this expression is seen
to be decreased in patients with CKD.79 By contrast, Scialla
et al.51 did not detect klotho expression in VSMCs in healthy
controls or in mice with CKD, and Lindberg et al.80 did not
detect klotho protein levels in arteries of wild-type mice.
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Fig. 2 – Diagram of BMD-CKD abnormalities and involvement in vascular calciﬁcation. CVD: cardiovascular disease; uP:
urine phosphorus; pP: plasma phosphorus.In uraemic rats, Ritter et al.81 found that klotho expres-
sion was high in the aortic adventitia and decreased in the
intima-media area.81
• Inhibition of 1-hydroxylase which produces hydroxylation
of 25-OH to 1,25(OH)2D317,82: Yoshida et al.82 demonstrated
in mice homozygous for the Kl(−/−) klotho gene that 1,25-
dihydroxyvitamin D levels were increased compared to
wild-type mice; at the same time, they conﬁrmed that
expression of the 1-hydroxylase gene was found to be
increased in Kl(−/−) mice and that administration of cal-
citriol failed to inhibit 1-hydroxylase.
Klotho has pleiotropic effects on a systemic level:
it increases transcription of erythropoietin receptors83;
reduces the damage caused by angiotensin II,70 inhibits the
insulin/IGF-1 signal, which may cause resistance to oxidative
stress84; shows antiﬁbrotic effects since it is able to inhibit the
transforming growth factor (TGF)  signal85; and has antise-
nescent and antiapoptotic effects.86
Involvement  of  klotho  in  CKD  and  CVR
As mentioned, klotho decreases early in CKD.19,72 Klotho deﬁ-
ciency may cause: vascular calciﬁcation as entry of P into
VSMCs is facilitated by klotho deﬁciency, arteriosclerosis,
osteoporosis, ectopic calciﬁcation, premature ageing, apopto-
sis and CKD progression.72,78,79,86 Klotho suppression also
leads to a reduction in phosphaturia resulting in hyperphos-
phatemia and increased serum levels of calcitriol. Studies in
experimental models have demonstrated a decrease in klothoin acute renal failure, and therefore klotho levels may be a
potential biomarker of acute renal failure.87,88 Likewise, some
authors propose that replacement of klotho may help a recov-
ery from acute renal damage.87,88
In the heart, klotho may directly inﬂuence cardiac func-
tion and remodelling by protecting it against LVH. Xie et al.89
assessed cardiac function and LVH in heterozygous mice hypo-
morphic for the (Kl/+) klotho allele with or without CKD and
wild-type mice with or without CKD. In mice with CKD, a drop
in klotho, LVH and myocardial ﬁbrosis was observed; all this
was less pronounced in klotho-heterozygous mice. Klotho-
heterozygous mice without CKD also had lower klotho levels,
but no evidence of LVH. Ejection fraction was signiﬁcantly
reduced in klotho-heterozygous mice with CKD. When soluble
klotho was injected into these mice, myocardial dysfunction
improved independently of P, FGF23, blood pressure and GFR.89
The cardioprotective effect of klotho may be due to the
inhibition of TRPC6 channel (transient receptor potential
family of cation channels in canonical subfamily) which is
increased in a uraemic state.89–91 When facing cardiological
aggression, TRPC6 allows greater entry of Ca into the cell,
which produces activation of the phosphatase calcineurin.
This causes dephosphorylation of NFAT that translocates to
the nucleus to induce expression of foetal gene (for example:
heavy chain -myosin). This leads to abnormal cardiac remod-
elling and LVH. The TRPC6 gene posses response elements
against NFAT and its expression is increased with cellular
92,93inﬂux of Ca, causing direct activation of the entire process.
In the future, if the TRPC6 channel is inhibited, klotho could
be used as a potential therapeutic strategy against LVH.
Fig. 2 outlines the involvement of FGF23 and klotho on CVR.
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onclusions
he search for early markers of CVR, inﬂammation and ﬁbrosis
hat may affect body economy and renal function is extensive.
MD-CKD plays a crucial role in endothelial and renal health,
nd so knowledge and management of it is a priority. Research
n FGF23 and klotho and their relationship to CVD is opening
ew expectations in both prevention and treatment.
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